Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients

Table 1

Baseline characteristics and rate of viral suppression by darunavir dose.

	All patients	DRV 1,200 mg daily	DRV 600 mg twice daily	DRV 800 mg daily	𝑃 value
𝑁	135	28	65	42
Age, yr, median (IQR)	47 (43–52)	48 (42–51)	46 (42–51)	49 (44–54)	0.174
Race/ethnicity					0.198
African American (%)	48.1	60.7	36.9	57.1
Caucasian (%)	33.3	25	38.5	31
Hispanic (%)	17	14.3	21.5	11.9
Other/unknown (%)	1.5	0	3.1	0
Baseline viral load					0.197
<1,000 copies/mL (%)	43	45.2	33.8	45.2
1,000–99,999 copies/mL (%)	40.7	40.5	46.2	40.5
≥100,000 copies/mL (%)	16.3	14.3	20	14.3
CD4+ cells/mL, mean (SD)	343.3	399.8 (355.1)	259.4 (229.6)	435.6 (283.5)	0.003
Concomitant ARVs, mean (SD)	2.2	1.86 (1.01)	2.55 (1.00)	1.93 (0.71)	<0.001
Baseline resistance
Baseline resistance testing available (𝑛)	109/135	20/28	57/65	32/42
Total DRV RAMs at baseline	72	5	66	1	<0.001
Baseline DRV RAMs, median (range)	0 (0–4)	0 (0–3)	1 (0–4)	0 (0-1)	<0.001
Patients with ≥1 documented DRV RAM (%)	28.9	10.7	53.8	2.4	<0.001
Endpoints
<50 copies/mL, 24 weeks (%)	49.6	53.6	52.3	42.9	0.568
<50 copies/mL, 48 weeks (%)	48.4	45.8	49.2	48.5	0.960